中国实用外科杂志2024，Vol.44Issue(2)：139-143,5.DOI:10.19538/j.cjps.issn1005-2208.2024.02.04
2023年版《Bethesda甲状腺细胞学分类诊断系统》更新要点及解读
Key updates and interpretation of the 2023 edition of the Bethesda System for Reporting Thyroid Cytopathology
摘要
Abstract
The 2023 edition of Bethesda System for Reporting Thyroid Cytopathology corresponds to the 2022 World Health Organization classification of thyroid tumors.In comparison to the 2010 and 2017 versions,significant updates in terms of diagnostic grading,recommended management approaches,and the assessment for risk of malignancy,as well as supplement of molecular testing have been made in the 2023 edition of Bethesda System for Reporting Thyroid Cytopathology.Distinct molecular events driving the dedifferentiation process in thyroid cancer have been identified,affirming the significance of molecular testing.As molecular testing continues to enhance the diagnostic efficacy of thyroid cancer,its application in the diagnosis and treatment of thyroid cancer is gradually expanding,with some instances even influencing surgical decision-making.However,both single-gene and multi-gene molecular testing still have limitations.Therefore,the widespread applicability of molecular testing in clinical practice to guide surgical decisions requires further research.关键词
甲状腺癌/Bethesda/分型/分子检测/手术方式Key words
thyroid cancer/Bethesda/pathological type/molecular testing/surgical approach分类
医药卫生引用本文复制引用
张福荣,赵萩阳,黄韬..2023年版《Bethesda甲状腺细胞学分类诊断系统》更新要点及解读[J].中国实用外科杂志,2024,44(2):139-143,5.基金项目
湖北省重点研发计划项目(No.2021BCA142) （No.2021BCA142）
